1. *Mycoplasma pneumoniae* infection may trigger asthma in children
===================================================================

ST. LOUIS (MD Consult)---*Mycoplasma pneumoniae* can cause acute respiratory infection and exacerbate symptoms of asthma, especially wheezing. *M. pneumoniae* may also play a role in the onset of asthma in children, according to the May 15 *Clinical Infectious Diseases.*

Dr. Sandra Biscardi and colleagues of Saint Vincent de Paul-Cochin Hospital in Paris prospectively studied 170 children between the ages of 2 and 15 years who were hospitalized for acute severe asthma. They also studied 152 children with stable asthma (*n*=113) or allergic rhinitis (*n*=39).

Nasopharyngeal specimens and blood samples were examined by polymerase chain reaction and serologic testing to identify *M. pneumoniae* and *Chlamydia pneumoniae.*

Of the 119 hospitalized patients with previously diagnosed asthma, 24 (20.2%) had *M. pneumoniae* infection, and 4 (3.4%) had *C. pneumoniae* infection.

Of the 51 hospitalized patients who were experiencing their first asthma attack, 26 (50%) had *M. pneumoniae* infection, and 3 (5.9%) had *C. pneumoniae* infection.

In comparison, both bacteria were significantly less common in the 152 controls with stable asthma or allergic rhinitis: 8 patients (5.2%) had *M. pneumoniae* infection, and 3 out of 120 patients tested (2.5%) had *C. pneumoniae* infection.

During the year after hospitalization, 24 of the 51 children who had been hospitalized with their first asthma attack had asthma recurrence. Recurrence rates were significantly higher in the 29 patients with *M. pneumoniae* (15 out of 26 patients; 57.7%) or *C. pneumoniae* (3 out of 3 patients; 100%) infection during the index hospitalization than in the 22 noninfected patients (6 out of 22 patients; 27.3%).

These findings reveal an association between lower respiratory tract infection with *M. pneumoniae* and (to a lesser extent) *C. pneumoniae* and the onset and exacerbation of childhood asthma.

*Clin Infect Dis* 2004;**38**:1341--6.

2. Beta-lactams should remain standard prophylaxis against SSIs after cardiac surgery
=====================================================================================

ST. LOUIS (MD Consult)---Beta-lactam drugs have been the gold standard for the prevention of surgical site infection (SSI) after cardiac surgery, but concerns about beta-lactam resistance have prompted some centers to switch to glycopeptides. However, a new meta-analysis finds no compelling evidence for making this switch, according to the May 15 *Clinical Infectious Diseases*.

Dr. Maureen K. Bolon and colleagues of Northwestern University Feinberg School of Medicine in Chicago and other institutions searched MEDLINE and relevant bibliographies to identify studies for consideration. Ultimately, they analyzed 7 randomized trials (5761 patients) that compared SSI rates of cardiac surgery patients receiving beta-lactam prophylaxis with those of patients receiving glycopeptide prophylaxis.

The 30-day SSI rate was 8.9%. Overall, as compared with patients receiving beta-lactam prophylaxis, glycopeptides were not significantly superior for preventing SSIs after cardiac surgery (risk ratio \[RR\], 1.14).

Still, subanalyses showed advantages for one regimen over the other in some instances. For example, beta-lactams were significantly superior for preventing chest SSIs (RR, 1.47). They also tended to be better for preventing deep chest SSIs (RR 1.33) and SSIs due to gram-positive bacteria (RR, 1.36).

On the other hand, glycopeptides were significantly superior for preventing SSIs due to methicillin-resistant gram-positive bacteria (RR, 0.54). Glycopeptides also tended to be better for preventing leg vein harvest site infection (RR, 0.77).

Some centers in which methicillin-resistant *Staphylococcus aureus* infection rates are high have switched to glycopeptides, and this switch may well prove wise. However, until a randomized, controlled study in such an environment can be completed, the authors advise against a global switch from beta-lactam to glycopeptide prophylaxis for patients undergoing cardiac surgery.

*Clin Infect Dis* 2004;**38**:1357--63.

3. *Echinacea purpurea* does not prevent experimental rhinovirus colds in humans
================================================================================

ST. LOUIS (MD Consult)---*Echinacea purpurea* (purple coneflower) is a popular herbal remedy used to prevent and treat the common cold. A randomized, double-blind, placebo-controlled trial, however, indicates that echinacea has no effect on experimentally induced infection with rhinovirus type 39.

Dr. Steven J. Sperber and colleagues of Hackensack University Medical Center in Hackensack, NJ, and other institutions discuss their findings in the May 15 *Clinical Infectious Diseases.*

The authors randomized 48 healthy adults to 14 days of treatment either with a formulation containing the pressed juice of the above-ground parts of *E. purpurea* in a 22% alcohol base (EchinaGuard; Madaus Aktiengesellschaft, Germany), or with a placebo that looked, smelled, and tasted the same as the active formulation. Treatments were packaged in identical 100-mL bottles and were taken in doses of 2.5 mL 3 times per day.

On day 7, subjects received an intranasal inoculation with rhinovirus type 39 (0.25 mL per nostril). Symptoms were recorded 3 times a day for the remaining 7 days of the study.

Infection was confirmed by culture and serologic studies in 92% of the echinacea group and 96% of the placebo group. Among the subjects with laboratory evidence of infection, the proportion of patients who developed colds did not differ significantly between the active drug and placebo groups (59% versus 86%, respectively).

Symptom scores were also similar between the 2 groups.

Granted, the sample size was small. Still, taking echinacea for 7 days before and 7 days after experimental rhinovirus infection did not prevent infection, nor did it reduce the number of colds or the number or severity of symptoms.

*Clin Infect Dis* 2004;**38**:1367--71.

4. Antifungal maintenance therapy for histoplasmosis can be safely stopped in AIDS patients responding to ART
=============================================================================================================

ST. LOUIS (MD Consult)---Antiretroviral therapy (ART) has dramatically reduced the incidence of opportunistic infections in patients with acquired immunodeficiency syndrome (AIDS). A new study indicates that patients with AIDS whose disease is controlled by ART can safely discontinue antifungal maintenance therapy for disseminated histoplasmosis.

These results, from Dr. Mitchell Goldman and Co-Investigators of the AIDS Clinical Trials Group A5038 Study Group, are published in the May 15 *Clinical Infectious Diseases.*

The authors prospectively studied 32 patients with human immunodeficiency virus who had previously had disseminated histoplasmosis but who had experienced no recurrence during 12 months of antifungal therapy. Additionally, all patients had received ≥6 months of ART and had CD4+ cell counts of \>150 cells/mm^3^.

Patients were followed for a median of 24 months to determine recurrences of disseminated histoplasmosis. During follow-up, the median CD4+ count improved from 289 to 338 cells/mm^3^, reflecting the patients\' positive response to ART.

During these 65 patient-years of follow-up, there were no recurrences of disseminated histoplasmosis. Furthermore, none of the patients had serum or urine antigen levels of \>4.1 units at any point during follow-up.

Thus, for patients with previous AIDS-related histoplasmosis who are responding to ART, antifungal maintenance therapy for disseminated histoplasmosis can be safely discontinued.

*Clin Infect Dis* 2004;**38**:1490--4.

5. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients
========================================================================================

Clinical and laboratory data on severe acute respiratory syndrome (SARS), particularly on the temporal progression of abnormal laboratory findings, are limited. We conducted a prospective study on the clinical, radiologic, and hematologic findings of SARS patients with pneumonia, who were admitted to National Taiwan University Hospital from March 8 to June 15, 2003. Fever was the most frequent initial symptom, followed by cough, myalgia, dyspnea, and diarrhea. Twenty-four patients had various underlying diseases. Most patients had elevated C-reactive protein (CRP) levels and lymphopenia. Other common abnormal laboratory findings included leukopenia, thrombocytopenia, and elevated levels of aminotransferase, lactate dehydrogenase, and creatine kinase. These clinical and laboratory findings were exacerbated in most patients during the second week of disease. The overall case-fatality rate was 19.7%. By multivariate analysis, underlying disease and initial CRP level were predictive of death.

*Emerg Infect Dis* \[serial online\] 2004 May \[cited 3 May 2004\]. Available from: [http://www.cdc.gov/ncidod/EID/vol10no5/03-0640.htm](http://www.cdc.gov/ncidod/eid/vol10no5/03-0640.htm).

6. Genetic variation of SARS coronavirus in Beijing hospital
============================================================

Xu D, Zhang Z, Chu F, Li Y, Jin L, Zhang L, et al.

To characterize genetic variation of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) transmitted in the Beijing area during the epidemic outbreak of 2003, we sequenced 29 full-length S genes of SARS-CoV from 20 hospitalized SARS patients on our unit, the Beijing 302 Hospital. Viral RNA templates for the S-gene amplification were directly extracted from raw clinical samples, including plasma, throat swab, sputum, and stool, during the course of the epidemic in the Beijing area. We used a TA-cloning assay with direct analysis of nested reverse transcription-polymerase chain reaction products in sequence. One hundred thirteen sequence variations with nine recurrent variant sites were identified in analyzed S-gene sequences compared with the BJ01 strain of SARS-CoV. Among them, eight variant sites were, we think, the first documented. Our findings demonstrate the coexistence of S-gene sequences with and without substitutions (compared to BJ01) in samples analyzed from some patients.

*Emerg Infect Dis* \[serial on the Internet\] 2004 May \[cited 3 May 2004\]. Available from: [http://www.cdc.gov/ncidod/EID/vol10no5/03-0875.htm](http://www.cdc.gov/ncidod/eid/vol10no5/03-0875.htm).

7. Multidrug-resistant strains of *Salmonella enterica* Typhimurium, United States, 1997--1998
==============================================================================================

Rabatsky-Ehr T, Whichard J, Rossiter S, Holland B, Stamey K, Headrick ML, et al.

To evaluate multidrug-resistant strains of *Salmonella enterica* serotype Typhimurium, including definitive type 104 (DT104) in the United States, we reviewed data from the National Antimicrobial Resistance Monitoring System (NARMS). In 1997 to 1998, 703 (25%) of 2,767 serotyped Salmonella isolates received at NARMS were *S. typhimurium*; antimicrobial susceptibility testing and phage typing were completed for 697. Fifty-eight percent (402) were resistant to \>1 antimicrobial agent. Three multidrug-resistant (\>5 drugs) strains accounted for 296 (74%) of all resistant isolates. Ceftriaxone resistance was present in 8 (3%), and nalidixic acid resistance in 4 (1%), of these multidrug-resistant strains. By phage typing, 259 (37%) of *S. typhimurium* isolates were DT104, 209 (30%) were of undefined type and 103 (15%) were untypable. Fifty percent (202) of resistant (\>1 drug) isolates were DT104. Multidrug-resistant *S. typhimurium* isolates, particularly DT104, account for a substantial proportion of *S. typhimurium* isolates; ceftriaxone resistance is exhibited by some of these strains.

*Emerg Infect Dis* \[serial on the Internet\] 2004 May \[cited 3 May 2004\]. Available from: [http://www.cdc.gov/ncidod/EID/vol10no5/03-0209.htm](http://www.cdc.gov/ncidod/eid/vol10no5/03-0209.htm).

8. Vancomycin susceptibility within methicillin-resistant *Staphylococcus aureus* lineages
==========================================================================================

Howe RA, Monk A, Wootton M, Walsh TR, Enright MC

Methicillin-resistant *Staphylococcus aureus* (MRSA) with reduced vancomycin susceptibility (vancomycin-intermediate *S. aureus* VISA) has been reported from many countries. Whether resistance is evolving regularly in different genetic backgrounds or in a single clone with a genetic predisposition, as early results suggest, is unclear. We have studied 101 MRSA with reduced vancomycin susceptibility from nine countries by multilocus sequence typing (MLST), characterization of SCCmec (staphylococcal chromosomal cassette mec), and agr (accessory gene regulator). We found nine genotypes by MLST, with isolates within all five major hospital MRSA lineages. Most isolates (88/101) belonged to two of the earliest MRSA clones that have global prevalence. Our results show that reduced susceptibility to vancomycin has emerged in many successful epidemic lineages with no clear clonal disposition. Increasing antimicrobial resistance in genetically distinct pandemic clones may lead to MRSA infections that will become increasingly difficult to treat.

*Emerg Infect Dis* \[serial on the Internet\] 2004 May \[cited 3 May 2004\]. Available from: [http://www.cdc.gov/ncidod/EID/vol10no5/03-0556.htm](http://www.cdc.gov/ncidod/eid/vol10no5/03-0556.htm).

9. Immunoblot method to detect *Streptococcus pneumoniae* and identify multiple serotypes from nasopharyngeal secretions
========================================================================================================================

Bronsdon MA, O\'Brien KL, Facklam RR, Whitney CG, Schwartz B, Carlone GM

Conventional culture techniques are limited in the ability to detect multiple *Streptococcus pneumoniae* serotypes in nasopharyngeal (NP) secretions. We developed an immunoblot (IB) method with monoclonal antibodies (MAbs) to detect *S. pneumoniae* and to identify serotypes. NP specimens stored in skim milk-tryptone-glucose-glycerol medium were assessed by the IB method and the reference culture method (RM). In the RM, four optochin-sensitive alpha-hemolytic colonies resembling pneumococci were typed by the Quellung reaction. In the IB method, a nitrocellulose membrane blot of surface growth was reacted with a pneumococcal surface adhesion (PsaA) MAb and visualized. Of 47 NP specimens, 32 (68%) were found to be positive and 13 (28%) were found to be negative for pneumococci by both methods; each method alone yielded one positive result. The sensitivity and specificity of the IB method for the detection of pneumococci were 97 and 93%, respectively. To identify serotypes, blots were tested with serotype-specific MAbs (4, 6A, 6B, 9V, 14, 18C, 19F, and 23F). To detect the remaining serotypes, positive serotype-specific replicate blots were compared visually to an original anti-PsaA-positive blot; four unidentified colonies were subcultured and serotyped by the Quellung reaction. Fifty-eight *S. pneumoniae*-positive NP specimens containing 69 pneumococcal strains (23 serotypes) were tested; 68 (98.6%) of the strains were detected by the IB method, and 66 (95.6%) were detected by the RM. For 11 specimens found to contain two serotypes, both methods detected both serotypes in 7 (63.6%), the IB method alone detected the two serotypes in 3 (27.3%), and the RM alone detected both serotypes in 1 (9%). The IB method identified multiple clones and minor populations of pneumococci in NP secretions. This method is useful for detecting specific serotypes and carriage of multiple serotypes in epidemiologic surveillance and carriage studies.

*J Clin Microbiol.* 2004 Apr; **42**(4):1596--600.

PMID: 15071010 \[PubMed---in process\]

10. Incidence of bloodstream infections due to *Candida* species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program
========================================================================================================================================================================================

Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, Phelan M, Morgan J, Lee-Yang W, Ciblak MA, Benjamin LE, Sanza LT, Huie S, Yeo SF, Brandt ME, Warnock DW

To determine the incidence of Candida bloodstream infections (BSI) and antifungal drug resistance, population-based active laboratory surveillance was conducted from October 1998 through September 2000 in two areas of the United States (Baltimore, MD, and the state of Connecticut; combined population, 4.7 million). A total of 1143 cases were detected, for an average adjusted annual incidence of 10 per 100,000 population or 1.5 per 10,000 hospital days. In 28% of patients, Candida BSI developed prior to or on the day of admission; only 36% of patients were in an intensive care unit at the time of diagnosis. No fewer than 78% of patients had a central catheter in place at the time of diagnosis, and 50% had undergone surgery within the previous 3 months. *Candida albicans* comprised 45% of the isolates, followed by *C. glabrata* (24%), *C. parapsilosis* (13%), and *C. tropicalis* (12%). Only 1.2% of *C. albicans* isolates were resistant to fluconazole (MIC, ≥64 μg/ml), compared to 7% of *C. glabrata* isolates and 6% of *C. tropicalis* isolates. Only 0.9% of *C. albicans* isolates were resistant to itraconazole (MIC, ≥1 μg/ml), compared to 19.5% of *C. glabrata* isolates and 6% of *C. tropicalis* isolates. Only 4.3% of *C. albicans* isolates were resistant to flucytosine (MIC, ≥32 μg/ml), compared to \<1% of *C. parapsilosis* and *C. tropicalis* isolates and no *C. glabrata* isolates. As determined by E-test, the MICs of amphotericin B were ≥0.38 μg/ml for 10% of Candida isolates, ≥1 μg/ml for 1.7% of isolates, and ≥2 μg/ml for 0.4% of isolates. Our findings highlight changes in the epidemiology of Candida BSI in the 1990s and provide a basis upon which to conduct further studies of selected high-risk subpopulations.

*J Clin Microbiol.* 2004 Apr;**42**(4):1519--27.

PMID: 15070998 \[PubMed---in process\]

11. Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of human immunodeficiency virus (HIV) type 1 RNA in patients with chronic HIV infection during structured treatment interruptions
======================================================================================================================================================================================================================

Prado JG, Shintani A, Bofill M, Clotet B, Ruiz L, Martinez-Picado J

Structured treatment interruptions (STIs) have been proposed as a potential treatment strategy during human immunodeficiency virus type 1 (HIV-1) antiretroviral therapy. This still-experimental intervention requires a close monitoring of patients\' plasma viremia and CD4(+)-T-cell counts during the treatment interruption phase. By using signal amplification of a heat-dissociated p24 antigen (p24Ag) assay, we compared p24Ag levels with levels of HIV RNA in plasma. One hundred seventy-four plasma samples were obtained from 51 chronically HIV-infected patients: 117 from patients who underwent STIs and 57 from patients who did not. Partial immune complex dissociation and clearance of those complexes by the erythrocytes were also investigated. A significant association between the two assays was observed (beta=0.23, 95% confidence interval=0.18, 0.28; *P*\<0.0001), but the association was smaller in the subset of samples from patients undergoing STIs. Moreover, discordant results and lack of longitudinal intrapatient correlation between levels of p24Ag and HIV-1 RNA were higher in this group. Incomplete immune complex dissociation and binding of those complexes to erythrocytes could be contributing factors involved in the diminished detection of p24Ag. Therefore, signal amplification of a heat-dissociated p24Ag had a positive association with current HIV RNA assays in a population-based analysis. However, it might not be sensitive enough to monitor longitudinal intrapatient viremia during STIs in patients with high CD4(+)-T-cell counts potentially due to the production of high-affinity anti-p24 antibodies and clearance of immune complexes by erythrocytes.

*J Clin Microbiol.* 2004 Apr;42(4):1620--5.

PMID: 15071015 \[PubMed---in process\]

12. Molecular analysis of adenovirus isolates from vaccinated and unvaccinated young adults
===========================================================================================

Blasiole DA, Metzgar D, Daum LT, Ryan MA, Wu J, Wills C, Le CT, Freed NE, Hansen CJ, Gray GC, Russell KL

Infections of adenovirus type 4 (Ad4) and Ad7 were discovered among previously vaccinated individuals through febrile respiratory illness surveillance at military recruit camps. Genetic analysis was performed on these isolates and a sample of adenovirus isolates from unvaccinated patients. Antigenic regions of the adenovirus hexon gene from 21 vaccinated and 31 unvaccinated patients were sequenced and compared to homologous regions of Ad4 and Ad7 vaccine strains and of other representative hexon sequences archived in GenBank. The phylogenetic distribution of sequences from vaccinated individuals closely resembled those from unvaccinated individuals. The most common Ad7 strain was the Ad7d2 hexon genotype, and the most common Ad4 strain was a genotype nearly identical to the recently discovered Z-G 95-873 Ad4 variant. Near exclusive isolation of Ad4 since 1999 indicates that the Ad4 variant is currently responsible for the vast majority of adenovirus morbidity in military recruit camps. Different ratios of nonsynonymous to synonymous nucleotide substitution rates in known antigenic regions compared to nonantigenic regions indicated positive selection for diversity in the antigenic regions and purifying selection in the nonantigenic regions.

*J Clin Microbiol.* 2004 Apr;**42**(4):1686--93.

PMID: 15071026 \[PubMed---in process\]

13. Secular trends in hospital-acquired *Clostridium difficile* disease in the United States, 1987--2001
========================================================================================================

Archibald LK, Banerjee SN, Jarvis WR

We reviewed *Clostridium difficile*-associated disease (CDAD) data from the intensive care unit (ICU) and hospital-wide surveillance components of the National Nosocomial Infections Surveillance System hospitals during 1987--2001. ICU CDAD rates increased significantly only in hospitals with \>500 beds (*P*\<0.01) and correlated with the duration of ICU stay (*r*=0.82; *P*\<0.05). Hospital-wide (non-ICU) rates increased only in hospitals with \<250 beds (*P*\<0.01) and in general medicine patients versus surgery patients (*P*\<0.0001). CDAD predominated in general hospitals versus other facility types, and rates were significantly higher during winter versus nonwinter months (*P*\<0.01). Thus, prevention efforts should be targeted to high-risk groups in these settings.

*J Infect Dis.* 2004 May 1; **189**(9):1585--9.

PMID: 15116293 \[PubMed---in process\]

14. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients
=============================================================================================================================================================

Boivin G, Goyette N, Gilbert C, Roberts N, Macey K, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Covington E

We investigated the emergence of cytomegalovirus (CMV) ganciclovir-resistance mutations in 301 high-risk solid-organ transplant (SOT) recipients after oral prophylaxis, for 100 days, with either valganciclovir or ganciclovir. For patients treated with ganciclovir, the incidence of CMV UL97 mutations was 1.9% (2/103) at the end of prophylaxis and 6.1% (2/33) for patients with suspected CMV disease up to 1 year after transplantation. No resistance mutations were detected in samples from valganciclovir-treated patients. Dual polymerase (UL54) and UL97 resistance mutations were not seen. Valganciclovir was associated with negligible risk of resistance and thus constitutes a useful alternative to ganciclovir prophylaxis for CMV in high-risk SOT recipients.

*J Infect Dis.* 2004 May 1; **189**(9):1615--8.

PMID: 15116297 \[PubMed---in process\]

15. Monophyletic relationship between severe acute respiratory syndrome coronavirus and group 2 coronaviruses
=============================================================================================================

Zhu G, Chen HW

Although primary genomic analysis has revealed that severe acute respiratory syndrome coronavirus (SARS CoV) is a new type of coronavirus, the different protein trees published in previous reports have provided no conclusive evidence indicating the phylogenetic position of SARS CoV. To clarify the phylogenetic relationship between SARS CoV and other coronaviruses, we compiled a large data set composed of 7 concatenated protein sequences and performed comprehensive analyses, using the maximum-likelihood, Bayesian-inference, and maximum-parsimony methods. All resulting phylogenetic trees displayed an identical topology and supported the hypothesis that the relationship between SARS CoV and group 2 CoVs is monophyletic. Relationships among all major groups were well resolved and were supported by all statistical analyses.

*J Infect Dis.* 2004 May 1; **189**(9):1676--8.

PMID: 15116304 \[PubMed---in process\]

16. Increase in prevalence of *Pneumocystis carinii* mutations in patients with AIDS and *P. carinii* pneumonia, in the United States and China
===============================================================================================================================================

Kazanjian PH, Fisk D, Armstrong W, Shulin Q, Liwei H, Ke Z, Meshnick S

This study of *Pneumocystis carinii* dihydropteroate synthase (DHPS) mutations in patients with AIDS who have *P. carinii* pneumonia compares the change in the prevalence of such mutations in the United States, where sulfa-drug prophylaxis is widespread, to that in China, where it is infrequent. The DHPS gene from 145 US patients presenting during 1983--2001 and from 15 Chinese patients presenting during 1998--2001 was amplified by polymerase chain reaction and was sequenced. In the United States, 40% of patients had DHPS mutations; 38% received sulfa-drug prophylaxis. Mutation prevalence increased to 70% during 2000--2001, from 25% during 1994--1995 (*P*\<0.01). In China, 7% of patients had DHPS mutations; none received sulfa-drug prophylaxis. The prevalence of *P. carinii* DHPS mutations has markedly increased in the United States but remains low in China.

*J Infect Dis.* 2004 May 1; **189**(9):1684--7.

PMID: 15116306 \[PubMed---in process\]
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